Form 4: Akari Therapeutics Director Gaslightwala Acquires 1,720,000 Ordinary Shares
SEC Form 4
Director Abizer Gaslightwala reports acquiring 1,720,000 ordinary shares of Akari Therapeutics Plc on January 3, 2025.
Summary
- On January 3, 2025, Abizer Gaslightwala, a director of Akari Therapeutics Plc, acquired 1,720,000 ordinary shares.
- The purchase prices ranged from $0.00064 to $0.000625 per ordinary share.
- Following the transaction, Gaslightwala beneficially owns 71,720,000 ordinary shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director's share purchase, which can be interpreted as a positive sign of confidence, but without further context, it's difficult to gauge the overall impact.
Positives
- A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders may view the director's purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of transaction: Abizer Gaslightwala acquired 1,720,000 Ordinary Shares. |
| 01/07/2025 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.